Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Annals of Neurology|March 10, 2011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaChris H Polman, Stephen C Reingold, Brenda Banwell, et al.
Archives of Neurology|October 12, 2005
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectationsElliot M Frohman, Olaf Stüve, Eva Havrdova, et al.
The Lancet. Neurology|November 3, 2009
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk scorePhilip L De Jager, Lori B Chibnik, Jing Cui, et al.
Brain and Behavior|October 1, 2016
Reliable measurements of brain atrophy in individual patients with multiple sclerosisDirk Smeets, Annemie Ribbens, Diana M Sima, et al.
Plos One|January 16, 2013
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET studyDana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension studyRalf Gold, Douglas L Arnold, Amit Bar-Or, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Annals of Neurology|March 10, 2011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaChris H Polman, Stephen C Reingold, Brenda Banwell, et al.
Archives of Neurology|October 12, 2005
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectationsElliot M Frohman, Olaf Stüve, Eva Havrdova, et al.
The Lancet. Neurology|November 3, 2009
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk scorePhilip L De Jager, Lori B Chibnik, Jing Cui, et al.
Brain and Behavior|October 1, 2016
Reliable measurements of brain atrophy in individual patients with multiple sclerosisDirk Smeets, Annemie Ribbens, Diana M Sima, et al.
Plos One|January 16, 2013
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET studyDana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, et al.
Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension studyRalf Gold, Douglas L Arnold, Amit Bar-Or, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Pageof 13